This is the third in a series of blogs covering the 58th ASH Annual Meeting and Exposition (#ASH16).
LLS’s groundbreaking precision medicine clinical trial in acute myeloid leukemia (AML), “has the potential to change the paradigm of AML and other hematologic malignancies,” said Kenneth Anderson, M.D., Dana-Farber Cancer Institute, during a press briefing today at the 58th ASH Annual Meeting and Exhibition in San Diego.
Dr. Anderson, president-elect of ASH (the American Society of Hematology) was the moderator of the press briefing about LLS’s Beat AML Master Trial, launched in October.
The three lead investigators of the trial, Brian Druker, M.D., OHSU Knight Cancer Institute, John Byrd, M.D., The Ohio State University Cancer Center and Ross Levine, M.D., Memorial Sloan Kettering Cancer Center, joined LLS CEO Louis J. DeGennaro, Ph.D., and LLS information specialist Gail Sperling, to discuss the rationale for a new approach to treating AML patients. Later in the day, Dr. Druker presented more details about the trial in a scientific spotlight session on precision medicine.